Parnaparin sodium oral

Drug Profile

Parnaparin sodium oral

Alternative Names: CB-01-05; CB-01-05-MMX™; Extended-release parnaparin sodium; LMW Heparin MMX; Low molecular weight heparin oral - Cosmo Pharmaceuticals

Latest Information Update: 15 Jun 2015

Price : $50

At a glance

  • Originator Cosmo Pharmaceuticals
  • Class Anticoagulants; Low molecular weight heparins; Vascular disorder therapies
  • Mechanism of Action Cytokine inhibitors; Interleukin 2 inhibitors; Tumour necrosis factor alpha inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase II Ulcerative colitis

Most Recent Events

  • 15 Jun 2015 Parnaparin sodium oral is still in phase II development for Ulcerative colitis in UK
  • 18 Feb 2014 Parnaparin sodium oral is still in phase II development for Ulcerative colitis in UK
  • 21 Apr 2008 Preliminary efficacy and adverse events data from a Phase-IIb trial in Ulcerative colitis released by Cosmo Pharmaceuticals
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top